MX2010005813A - Conjugados oligomero-triciclicos. - Google Patents
Conjugados oligomero-triciclicos.Info
- Publication number
- MX2010005813A MX2010005813A MX2010005813A MX2010005813A MX2010005813A MX 2010005813 A MX2010005813 A MX 2010005813A MX 2010005813 A MX2010005813 A MX 2010005813A MX 2010005813 A MX2010005813 A MX 2010005813A MX 2010005813 A MX2010005813 A MX 2010005813A
- Authority
- MX
- Mexico
- Prior art keywords
- oligomer
- tricyclic
- conjugates
- water soluble
- small molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyethers (AREA)
Abstract
La invención proporciona fármacos de moléculas pequeñas que están modificados químicamente por unión covalente de un oligómero soluble en agua; un conjugado de la invención, cuando se administra por cualquiera de varias rutas de administración, exhibe características que son diferentes de las características del fármaco de molécula pequeña no unido al oligómero soluble en agua.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US448307P | 2007-11-28 | 2007-11-28 | |
US19163508P | 2008-09-10 | 2008-09-10 | |
PCT/US2008/013221 WO2009073154A1 (en) | 2007-11-28 | 2008-11-28 | Oligomer-tricyclic conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010005813A true MX2010005813A (es) | 2010-06-15 |
Family
ID=40342742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005813A MX2010005813A (es) | 2007-11-28 | 2008-11-28 | Conjugados oligomero-triciclicos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8569380B2 (es) |
EP (1) | EP2222342B1 (es) |
JP (1) | JP5643103B2 (es) |
KR (1) | KR101539797B1 (es) |
CN (1) | CN101878042B (es) |
AU (1) | AU2008331868B2 (es) |
CA (1) | CA2704836C (es) |
HK (1) | HK1147212A1 (es) |
IL (1) | IL205966A (es) |
MX (1) | MX2010005813A (es) |
WO (1) | WO2009073154A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8796248B2 (en) * | 2007-10-05 | 2014-08-05 | Nektar Therapeutics | Oligomer-corticosteroid conjugates |
MX2010005813A (es) | 2007-11-28 | 2010-06-15 | Nektar Therapeutics | Conjugados oligomero-triciclicos. |
WO2011091050A1 (en) * | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
EP2648707B1 (en) * | 2010-12-10 | 2016-05-11 | Nektar Therapeutics | Hydroxylated tricyclic compounds |
WO2012088529A1 (en) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
WO2012088522A1 (en) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
CN105085465A (zh) * | 2015-08-17 | 2015-11-25 | 苏州黄河制药有限公司 | 一种以邻卤甲基苯甲酸甲酯为原料合成盐酸多塞平的方法 |
CN105367538A (zh) * | 2015-11-26 | 2016-03-02 | 苏州黄河制药有限公司 | 一种以邻卤甲基苯甲酸甲酯为原料制备盐酸多塞平的方法 |
CA3062738C (en) | 2016-05-02 | 2023-03-14 | James Roy Brownlee | Replaceable absorbent diaper channel for use as a multiplier with single-use disposable diapers or re-usable recyclable outer shell |
CA3154630A1 (en) | 2019-10-21 | 2021-04-29 | Mark E. Duggan | 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propano ic acid derivatives as h1 and 5-ht2a-receptor modulators for the treatment of sleep disorders |
CN110698451A (zh) * | 2019-10-29 | 2020-01-17 | 山东诚汇双达药业有限公司 | 取代二苯并[ b,e ]硫(氧)杂七环-11(6H)-酮类化合物及其制备方法 |
CN112410385B (zh) * | 2020-11-24 | 2022-07-22 | 江南大学 | 一种细胞色素p450环氧酶及其应用 |
CN114702453B (zh) * | 2022-03-29 | 2024-02-02 | 江西师范大学 | 11-(三氟甲基)-二苯并[b,e][1,4]二氮杂卓系列化合物及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2948718A (en) * | 1960-08-09 | New n-heterocyclic compounds | ||
US2554736A (en) * | 1951-05-29 | Tertiary aminoalkyl-iminodibenzyls | ||
US3282942A (en) * | 1966-11-01 | Substituted cycloalkanoindoles | ||
CH368178A (de) | 1958-09-10 | 1963-03-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen basisch substituierten heterocyclischen Verbindungen |
NL110232C (es) * | 1958-12-06 | |||
US3409640A (en) * | 1959-07-22 | 1968-11-05 | Schering Corp | 5-(3'-dimethylamino-2'-methyl-propyl)dibenzocycloheptenes |
NL256049A (es) | 1959-09-22 | |||
NL274885A (es) * | 1960-09-16 | |||
US3454554A (en) * | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
NL279409A (es) * | 1961-06-08 | |||
CH426833A (de) * | 1962-03-27 | 1966-12-31 | Dumex Ltd As | Verfahren zur Herstellung des N-Oxyds des N-(3-Dimethylamino-propyl)-iminodibenzyls oder seiner Salze |
US3205264A (en) * | 1962-06-15 | 1965-09-07 | Merck & Co Inc | Process for the preparation of 10, 11-dihydro-5-(gamma-methyl-and dimethyl-amino propylidene)-5h-dibenzo[a, d] cycloheptene |
US3271451A (en) * | 1962-07-03 | 1966-09-06 | Merck & Co Inc | Process for preparing 5-(3-methylaminopropyl)-5h-dibenzo [a, d] cycloheptenes |
US3244748A (en) * | 1962-07-03 | 1966-04-05 | Merck & Co Inc | 5h-dibenzo [a, d] cycloheptenes |
NL130095C (es) * | 1962-08-31 | |||
US3258399A (en) * | 1962-09-13 | 1966-06-28 | Colgate Palmolive Co | Method of inducing central nervous system stimulation |
US3420851A (en) * | 1962-12-19 | 1969-01-07 | Pfizer & Co C | Novel dibenzoxepines |
GB991651A (en) * | 1963-02-20 | 1965-05-12 | Dumex Ltd As | Dibenzocycloheptadiene derivatives |
FR88751E (es) * | 1963-07-09 | 1967-06-07 | ||
CH433303A (de) | 1963-08-05 | 1967-04-15 | Sandoz Ag | Verfahren zur Herstellung neuer carbocyclischer Verbindungen |
US3452009A (en) * | 1965-05-03 | 1969-06-24 | Merck & Co Inc | 2,3-epoxypropylidene derivative of 5h-dibenzo(a,d)-10,11-dihydrocycloheptenes |
US3963778A (en) * | 1965-11-10 | 1976-06-15 | Bayer Aktiengesellschaft | Basic oximes and their preparation |
GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
FR1532301A (fr) * | 1967-01-18 | 1968-07-12 | Rhone Poulenc Sa | Nouveaux dérivés de la dibenzazépine et leur préparation |
GB1177525A (en) * | 1967-04-13 | 1970-01-14 | Leo Ab | New Heterocyclic Aminoketones of Therapeutic Interest |
GB1191800A (en) | 1968-12-10 | 1970-05-13 | Nii Farmakologii I Khim | 00-(beta-Diethylaminopropionyl)-2-Trifluoromethylphenothiazine Hydrochloride |
CH500196A (de) * | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
GB1269551A (en) | 1969-03-27 | 1972-04-06 | Science Union & Cie | New tricyclic derivatives and process for their manufacture |
US3758528A (en) * | 1970-03-13 | 1973-09-11 | Science Union & Cie | Tricyclic compounds |
US4250094A (en) * | 1971-04-28 | 1981-02-10 | The Upjohn Company | 1-(Aminoalkyl) substituted-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
US4097597A (en) * | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
ATE13297T1 (de) * | 1980-09-02 | 1985-06-15 | Sandoz Ag | Piperidyliden-derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
US5783178A (en) | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US6214820B1 (en) * | 1998-10-21 | 2001-04-10 | Novo Nordisk A/S | Compounds, their preparation and use |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
AR047938A1 (es) | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
WO2005058367A2 (en) | 2003-12-16 | 2005-06-30 | Nektar Therapeutics Al, Corporation | Pegylated small molecules |
CA2556380A1 (en) * | 2004-03-02 | 2005-09-15 | Pharmacia Corporation | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
CA2597306A1 (en) | 2005-02-14 | 2006-08-24 | Combinatorx, Incorporated | Compounds and uses thereof |
US8029355B2 (en) * | 2006-12-19 | 2011-10-04 | Igt | Configurable gaming device with player selectable award profile |
TW200836747A (en) | 2007-01-05 | 2008-09-16 | Combinatorx Inc | Methods, compositions, and kits for the treatment of pain |
US8389759B2 (en) * | 2007-03-12 | 2013-03-05 | Nektar Therapeutics | Oligomer-anticholinergic agent conjugates |
MX2010005813A (es) | 2007-11-28 | 2010-06-15 | Nektar Therapeutics | Conjugados oligomero-triciclicos. |
WO2009151590A2 (en) | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Methods of treating cyp2d6 alternative metabolizers |
CA2749126C (en) | 2009-01-28 | 2017-08-22 | Nektar Therapeutics | Oligomer-phenothiazine conjugates |
-
2008
- 2008-11-28 MX MX2010005813A patent/MX2010005813A/es active IP Right Grant
- 2008-11-28 WO PCT/US2008/013221 patent/WO2009073154A1/en active Application Filing
- 2008-11-28 CA CA2704836A patent/CA2704836C/en active Active
- 2008-11-28 CN CN2008801181543A patent/CN101878042B/zh active Active
- 2008-11-28 AU AU2008331868A patent/AU2008331868B2/en active Active
- 2008-11-28 US US12/744,467 patent/US8569380B2/en active Active
- 2008-11-28 EP EP08857684.8A patent/EP2222342B1/en active Active
- 2008-11-28 KR KR1020107011331A patent/KR101539797B1/ko active IP Right Grant
- 2008-11-28 JP JP2010536016A patent/JP5643103B2/ja active Active
-
2010
- 2010-05-26 IL IL205966A patent/IL205966A/en active IP Right Grant
-
2011
- 2011-02-15 HK HK11101446.5A patent/HK1147212A1/xx unknown
-
2013
- 2013-09-06 US US14/020,196 patent/US9725431B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9725431B2 (en) | 2017-08-08 |
IL205966A0 (en) | 2010-11-30 |
CN101878042B (zh) | 2013-06-19 |
CN101878042A (zh) | 2010-11-03 |
CA2704836A1 (en) | 2009-06-04 |
US8569380B2 (en) | 2013-10-29 |
US20140100268A1 (en) | 2014-04-10 |
HK1147212A1 (en) | 2011-08-05 |
JP5643103B2 (ja) | 2014-12-17 |
EP2222342B1 (en) | 2014-03-26 |
EP2222342A1 (en) | 2010-09-01 |
US20100298296A1 (en) | 2010-11-25 |
AU2008331868A1 (en) | 2009-06-11 |
WO2009073154A1 (en) | 2009-06-11 |
JP2011504928A (ja) | 2011-02-17 |
CA2704836C (en) | 2015-12-29 |
KR20100093059A (ko) | 2010-08-24 |
KR101539797B1 (ko) | 2015-07-27 |
AU2008331868B2 (en) | 2015-02-12 |
IL205966A (en) | 2014-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010005813A (es) | Conjugados oligomero-triciclicos. | |
MX2009009851A (es) | Conjugados de agonistas de oligomeros-opioides. | |
MX2009009850A (es) | Conjugados de inhibidor de oligomero-proteasa. | |
WO2009042064A3 (en) | Oligomer-nucleoside phosphate conjugates | |
CY1112278T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους | |
WO2005058367A3 (en) | Pegylated small molecules | |
WO2009099670A3 (en) | Oligomer-cannabinoid conjugates | |
NZ720743A (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
ATE524473T1 (de) | Zytotoxische verbindungen | |
NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
WO2007103288A3 (en) | Engineered antibody drug conjugates | |
WO2007130491A3 (en) | Patient customized therapeutic regimens | |
WO2008112873A3 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
WO2007137170A3 (en) | Anti-glypican-3 antibody drug conjugates | |
PT2057139E (pt) | Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais | |
WO2011002852A3 (en) | Pro-drug complexes and related methods of use | |
WO2016147031A3 (en) | Novel hydrophilic linkers and ligand-drug conjugates thereof | |
WO2011054837A3 (de) | Bifunktionale prodrugs und drugs | |
CA3010551A1 (en) | Pyrrolobenzodiazepine conjugates | |
MX2012010448A (es) | Conjugados de carbohidrato-poli aminoacido-farmaco. | |
EA200900958A1 (ru) | Препарат невирапина пролонгированного высвобождения | |
WO2009058387A3 (en) | Oligomer-nitroimidazole anti-infective conjugates | |
MX2011007940A (es) | Conjugados de oligomero-fenotiazina. | |
UA102216C2 (ru) | 4-гидрокситиобензамидные производной лекарственных веществ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |